Physician profile
Debra Castner
NPI 1134212939
$28,314.91
in general payments reported to CMS, 2019-2025
13 companies · $605 in 2025
The $605 reported for 2025 was more than what 80% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23K · 2022: $2,465 · 2023: $2,033 · 2024: $487 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,815 · Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,815.00 |
| Food and Beverage | $1,310.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22,683.55 | 2021-2022 | |
| Glaxosmithkline, LLC. | $3,817.82 | 2022-2023 | |
| Vifor Pharma, INC. | $293.97 | 2022-2024 | Veltassa |
| Amgen INC. | $262.12 | 2024 | Aranesp, Parsabiv, Sensipar |
| Travere Therapeutics, INC. | $250.00 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $199.99 | 2024-2025 | |
| Ardelyx, INC. | $140.00 | 2025 | Xphozah 30 Mg |
| Outset Medical INC | $125.00 | 2025 | |
| Calliditas Therapeutics US INC. | $122.82 | 2023 | Tarpeyo |
| Cormedix INC. | $120.00 | 2025 | Defencath |
| Akebia Therapeutics INC | $120.00 | 2025 | Vafseo |
| Novartis Pharmaceuticals Corporation | $95.47 | 2023 | |
| Abbvie INC. | $84.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Castner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.